Decoy Therapeutics (DCOY) risk factors

Item 1A of every Decoy Therapeutics Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open DCOY in Gloom →

Decoy Therapeutics' chart, financials and news, free in your browser.Open DCOY in Gloom →

FY2025 10-K risk factors
59 risks53 new33 dropped5 reworded
Nasdaq requires the company to regain its $1.00 bid-price compliance by March 20, 2026 or face delisting.
Filed Mar 31, 2026
FY2024 10-K risk factors
39 risks
Decoy Therapeutics faces primary risks centered on its pending merger with Salarius, including potential cash shortfalls and Nasdaq delisting. The company relies entirely on unproven oncology therapeutics without commercial revenue or funds for clinical trials.
Filed Mar 21, 2025